In vivo delivery of interleukin-4 by a recombinant vaccinia virus prevents tumor development in mice

Human Gene Therapy

Volumn 5, Issue 7, 1994, Pages 809-820

  Elkins, Karen L ^a,b,e   Ennist, David L ^c,d   Winegar, Robert K ^b   Weir, Jerry P ^b  

^a CENTER FOR BIOLOGICS EVALUATION AND RESEARCH   (United States)

^b WALTER REED ARMY INSTITUTE OF RESEARCH   (United States)

^c EUNICE KENNEDY SHRIVER NATIONAL INSTITUTE OF CHILD HEALTH AND HUMAN DEVELOPMENT   (United States)

^d NOVARTIS PHARMA AG   (Switzerland)

^e CENTER FOR DRUG EVALUATION AND RESEARCH   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

CYTOKINE; IMMUNOMODULATING AGENT; INTERLEUKIN 4; THYMIDINE KINASE;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ANTINEOPLASTIC ACTIVITY; ARTICLE; CARCINOGENESIS; CLONING VECTOR; CONTROLLED STUDY; GENE; GENE THERAPY; MALE; MOUSE; NONHUMAN; PLAQUE FORMING CELL; SUBCUTANEOUS DRUG ADMINISTRATION; SUBCUTANEOUS TISSUE TUMOR; T LYMPHOCYTE; VACCINIA VIRUS; VIRUS RECOMBINANT;

ANIMALIA; MURINAE; VACCINIA; VACCINIA VIRUS;

EID: 0027992479     PISSN: 10430342     EISSN: None     Source Type: Journal    
DOI: 10.1089/hum.1994.5.7-809     Document Type: Article

References (48)

1. AKASHI, K., SHIBUYA, T., HARADA, M., TAKAMATSU, Y., UIKE, N., ETO, T., and NIHO Y. (1991). Interleukin 4 suppresses the spontaneous growth of chronic myelomonocytic leukemia cells. J. Clin. Invest. 88, 223-230.
2. ANDREW, M.E., and COUPAR, B.E.H. (1992). Biological effects of recombinant vaccinia virus-expressed interleukin 4. Cytokine 4, 281-286.
3. AUSUBEL, F.M., BRENT, R., KINGSTON, R.E., MOORE, D.D., SMITH, J.A., SEIDMAN, J.G., and STRUHL, K., eds. (1991). Current Protocols in Molecular Biology. (Green Publishing Associates, New York).
4. BERNARDS, R., DESTREE, A., MCKENZIE, S., GORDON, E., WEINBERG, R.A., and PANICALI, D. (1987). Effective tumor immunotherapy directed against an oncogene-encoded product using a vaccinia virus vector. Proc. Natl. Acad. Sci. USA 84, 6854-6858.
5. BLANKENSTEIN, T., LI, W., MÜLLER, W., and DIAMANTSTEIN, T. (1990). Retroviral interleukin 4 gene transfer into an interleukin 4-dependeut cell line results in autocrine growth but not in tumorigenicity. Eur. J. Immunol. 20, 935-938.
6. BOSCO, M., GIOVARELLI, M., FORNI, M., MODESTI, A., SCARPA, S., MASUELLI, L., and FORNI, G. (1990). Low doses of IL-4 injected perilymphatically in tumor-bearing mice inhibit the growth of poorly and apparently nonimmunogenic tumors and induce a tumor-specific immune memory. J. Immunol. 145, 3136-3143.
7. BRENAN, M., and ZINKERNAGEL, R.M. (1983). Influence of one virus infection on a second concurrent primary in vivo antiviral cytotoxic T-cell response. Infect. Immun. 41, 470-475.
8. BULLER, R.M.L., and PALUMBO, G.J. (1991). Poxvirus pathogenesis. Microbiol. Rev. 55, 80-122.
9. BULLER, R.M.L , SMITH, G.L., CREMER, K., NOTKINS, A.L., and MOSS, B. (1985). Decreased virulence of recombinant vaccinia virus expression vectors is associated with a thymidine kinase-negative phenotype. Nature 317, 813-815.
10. CHAKRABARTI, S., BRECHLING, K., and MOSS, B. (1985). Vaccinia virus expression vector. coexpression of β-galactosidase provides visual screening of recombinant virus plaques. Mol. Cell. Biol. 5, 3403-3409.
11. CORCORAN, L.M , METCALF, D., EDWARDS, S.J., and HANDMAN, E. (1988). GM-CSF produced by recombinant vaccinia virus or in GM-CSF transgenic mice has no effect in vivo on murine cutaneous Leishmaniasis. J. Parasitol. 74, 763-767.
12. CUSTER, M.C., and LOTZE, M.T. (1990). A biologic assay for IL-4. Rapid fluorescence assay for IL-4 detection in supernatants and serum. J. Immunol. Methods 128, 109-117.
13. FERNANDEZ-BOTRAN, R., and VITETTA, E.S. (1991). Evidence that natural murine soluble interleukin 4 receptors may act as transport proteins. J. Exp. Med. 174, 673-681
14. FLEXNER, C., HÜGIN, A., and MOSS, B. (1987). Prevention of vaccinia virus infection in immunodeficient mice by vector-directed IL-2 expression. Nature 330, 259-262.
15. FLEXNER, C., MURPHY, B.R., ROONEY, J.F., WOHLENBERG, C., YUFEROV, V., NOTKINS, A L., and MOSS, B. (1988). Successful vaccination with a polyvalent live vector despite existing immunity to an expressed antigen. Nature 335, 259-262.
16. GOLUMBEK, P.T., LAZENBY, A.J., LEVITSKY, H.I., JAFFEE, L.M., KARASUYAMA, H., BAKER, M., and PARDOLL, D.M. (1991). Treatment of established renal cancer by tumor cells engineered to secrete interleukin-4. Science 254, 713-716.
17. HAREUVENI, M., GAUTIER, C , KIENY, M.-P., WRESCHNER, D., CHAMBON, P., and LATHE, R. (1990). Vaccination against tumor cells expressing breast cancer epithelial tumor antigens. Proc. Natl. Acad. Sci. USA 87, 9498-9502.
18. HOON, D.S.B., BANEZ, M , OKUM, E., MORTON, D.L., and IRIE, R.F (1991a). Modulation of human melanoma cells by interleukin-4 and in combination with gamma-interferon or alpha-tumor necrosis factor. Cancer Res. 51, 2002-2008.
19. HOON, D.S.B., OKUN, E , BANEZ, M., IRIE, R.F., and MORTON, D.L. (1991b). Interleukin 4 alone and with gamma-interferon or alphatumor necrosis factor inhibits cell growth and modulates cell surface antigens on human renal cell carcinoma. Cancer Res. 51, 5687-5693.
20. HU, S-L., PLOWMAN, G.D., SRIDHAR, P., STEVENSON, U.S., BROWN, J.P., and ESTIN, C D. (1988). Characterization of a recombinant vaccinia virus expressing human melanoma-associated antigen p97. J. Virol. 62, 176-180.
21. HU-LI, J., OHARA. J., WATSON, C , TSANG, W., and PAUL, W.E. (1989). Derivation of a T cell line that is highly responsive to IL-4 and IL-2 (CT.4R) and of an IL-2 hyporesponsive mutant of that line (CT.4S) J Immunol. 142, 800-807.
22. KARUPIAH, G., COUPAR, B E.H., ANDREW, M., BOYLE, D.B., PHILLIPS, S M., MULLBACHER, A., BLANDEN, R.V., and RAMSHAW, I. (1990a). Elevated natural killer cell responses in mice infected with recombinant vaccinia virus encoding murine IL-2. J. Immunology 144, 290-298.
23. KARUPIAH, G., COUPAR, B., RAMSHAW, I., BOYLE, D., BLANDEN, R., and ANDREW, M. (1990b). Vaccinia virus-mediated damage of murine ovaries and protection by virus-expressed interleukin-2 Immunol. Cell Biol. 68, 325-333.
24. KOHONEN-CORISH, M.R.J , KING, N.J.C., WOODHAMS, C.E., and RAMSHAW, I.A. (1990). Immunodeficient mice recover from infection with vaccinia virus expressing interferon-gamma. Eur. J. Immunol. 20, 157-161.
25. KÜHN, R., RAJEWSKY, K., and MÜLLER. W. (1991). Generation and analysis of interleukin-4 deficient mice. Science 254, 707-710.
26. LEE, F., YOKOTA, T , OTSUKA, T., MEYERSON, P., VILLARET, D., COFFMAN, R., MOSMANN, T., RENNICK, D., ROEHM, N., SMITH, C., ZLOTNIK, A., and ARAI, K. (1986). Isolation and characterization of a mouse interleukin cDNA clone that expresses B-cell stimulatory factor 1 activities and T-cell- and mast-cell-stimulating activities. Proc. Natl. Acad. Sci. USA 83, 2061-2065.
27. LOTZE, M.T., CUSTER, M.C., BOLTON, E.S., WIEBKE, E.A., KAWAKAMI, Y., and ROSENBERG, S.A. (1990). Mechanisms of immunologic antitumor therapy: lessons from the laboratory and clinical applications. Human Immunol. 28, 198-207.
28. MACKETT, M., SMITH, G.L., and MOSS, B. (1985). The construction and characterisation of vaccinia virus recombinants expressing foreign genes. In DNA Cloning: A Practical Approach, vol. II. D.M. Glover, ed. (IRL Press Limited, Oxford) pp. 191-211.
29. MILLER, A.D. (1992). Human gene therapy comes of age. Nature 357, 455-460.
30. MILLER, J. (1972). Experiments in Molecular Genetics. (Cold Spring Harbor Laboratory, Cold Spring Harbor, NY)
31. MULÉ, J J., SMITH, C.A., and ROSENBERG, S.A (1987). Interleukin 4 (B cell stimulatory factor 1) can mediate the induction of lymphokine-activated killer cell activity directed against fresh tumor cells. J. Exp. Med. 166, 792-797.
32. PARDOLL, D. (1992). New strategies for active immunotherapy with genetically engineered tumor cells. Curr. Opin. Immunol. 4, 619-623
33. PAUL, W.E (1987). Interleukin 4/B cell stimulatory factor 1: One lymphokine, many functions. FASEB J 1, 456-461.
34. RAMSHAW, I.A., ANDREW, M E., PHILLIPS, S.M., BOYLE, D.B., and COUPAR, B E.H. (1987). Recovery of immunodeficient mice from a vaccinia virus/IL-2 recombinant infection. Nature 329, 545-546.
35. RAMSHAW, I., RUBY, J., RAMSAY, A., ADA, G., and KARUPIAH, G. (1992). Expression of cytokines by recombinant vaccinia viruses: a model for studying cytokines in virus infections in vivo. Immunol. Rev. 127, 157-182.
36. ROONEY, J.F., WOHLENBERG, C., CREMER, K.H., MOSS, B., and NOTKINS, A.L. (1988). Immunization with a vaccinia virus recombinant expressing Herpes Simplex Virus type 1 glycoprotein D: long-term protection and effect of revaccination. J. Virol. 62, 1530-1534.
37. ROSENBERG, S.A. (1991). Immunotherapy and gene therapy of cancer. Cancer Res. 51, 5074-5079.
38. RUBIN, J T., and LOTZE, M.T. (1992). Acute gastric mucosal injury associated with the systemic administration of interleukin-4 Surgery 111, 274-280.
39. RUSSELL, S.J (1990) Lymphokine gene therapy for cancer. Immunol. Today 11, 196-200.
40. SAMBI, S.K., KOHONEN-CORISH, M.R.J., and RAMSHAW, I.A. (1991). Local production of tumor necrosis factor encoded by recombinant vaccinia virus in effective in controlling viral replication in vivo Proc. Natl Acad Sci. USA 88, 4025-4029.
41. SANFORD, K.K., MERWIN, R.M., HOBBS, G.L., FIORAMONTI, M.C., and EARLE, W.R. (1958). Studies on the difference in sarcoma-producing capacity of two lines of mouse cells derived in vitro from one cells. J. Natl. Cancer Inst 20, 121-145
42. TEPPER, R.I , PATTENGALE, P.K., and LEDER, P. (1989). Murine interleukin-4 displays potent anti-tumor activity in vivo. Cell 57, 503-512.
43. TEPPER, R.I., LEVINSON, D.A., STANGER, B.Z., CAMPOSTORRES, J., ABBAS, A.K., and LEDER, P. (1990). IL-4 induces allergic-like inflammatory disease and alters T cell development in transgenic mice. Cell 62, 457-467.
44. TEPPER, R.I., COFFMAN, R.L , and LEDER, P (1992). An eosinophil-dependent mechanism for the antitumor effect of interleukin-4. Science 257, 548-551.
45. TOI, M., BICKNELL, R., and HARRIS, A.L. (1992). Inhibition of colon and breast carcinoma cell growth by Interleukin-4. Cancer Res. 52, 275-279.
46. WEIR, J.P., and ELKINS, K.L. (1993). Replication-incompetent herpesvirus vector delivery of an interferon alpha gene inhibits human immunodeficiency virus replication in human monocytes. Proc. Natl. Acad. Sci. USA 90, 9140-9144.
47. WEIR, J.P., BENNETT, M., ALLEN, E.M., ELKINS, K.L., MARTIN, S., and ROUSE, B.T. (1989). Recombinant vaccinia virus expressing the herpes simplex virus type 1 glycoprotein C protects mice against herpes simplex virus challenge. J. Gen. Virol. 70, 2587-2594.
48. YASUMUTA, Y., TASHJIAN, A.H., and SATO, G. (1966). Establishment of four functional, clonal strains of animal cells in culture. Science 154, 1186-1189.